4DMT to Participate in Upcoming Investor Conferences
Rhea-AI Summary
4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, has announced its participation in three major investor conferences in September 2025. The management team will engage in fireside chats and be available for one-on-one meetings at the following events:
- Cantor Global Healthcare Conference on September 4 at 11:30 a.m. ET
- H.C. Wainwright Global Investment Conference on September 9 at 10:00 a.m. ET
- Morgan Stanley Global Healthcare Conference on September 9 at 1:50 p.m. ET
Webcasts of the presentations will be available on the company's investor relations website, with archived recordings accessible for up to one year.
Positive
- None.
Negative
- None.
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in September. Members of the management team will also be available for one-on-one meetings.
Cantor Global Healthcare Conference 2025
| Presentation Date: | Thursday, Sept 4, 2025 |
| Presentation Time: | 11:30 a.m. ET |
| Webcast Link: | Webcast |
H.C. Wainwright 27th Annual Global Investment Conference
| Presentation Date: | Tuesday, Sept 9, 2025 |
| Presentation Time: | 10:00 a.m. ET |
| Webcast Link: | Webcast |
Morgan Stanley Annual Global Healthcare Conference
| Presentation Date: | Tuesday, Sept 9, 2025 |
| Presentation Time: | 1:50 p.m. ET |
| Webcast Link: | Webcast |
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the Cantor Global Healthcare Conference 2025?
How many investor conferences will FDMT attend in September 2025?
Where can investors access FDMT's conference presentations?
What type of meetings will FDMT management offer at these conferences?
